{"organizations": [], "uuid": "e3c69c3ddc50b2bf24874fd181cf03a8518f9eb4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180329.html", "section_title": "Archive News &amp; Video for Thursday, 29 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-indivior-says-enters-into-license/brief-indivior-says-enters-into-license-agreement-for-c4x-discoverys-ox1-antagonist-program-idUSFWN1RB03A", "country": "US", "domain_rank": 408, "title": "‍Indivior Says Enters Into License Agreement For C4x Discovery's OX1 Antagonist Program​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.84, "site_type": "news", "published": "2018-03-29T15:11:00.000+03:00", "replies_count": 0, "uuid": "e3c69c3ddc50b2bf24874fd181cf03a8518f9eb4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-indivior-says-enters-into-license/brief-indivior-says-enters-into-license-agreement-for-c4x-discoverys-ox1-antagonist-program-idUSFWN1RB03A", "ord_in_thread": 0, "title": "‍Indivior Says Enters Into License Agreement For C4x Discovery's OX1 Antagonist Program​", "locations": [], "entities": {"persons": [], "locations": [{"name": "indivior uk", "sentiment": "none"}, {"name": "uk", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - Indivior Plc:\n* ‍INDIVIOR ENTERS INTO AN EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR C4X DISCOVERY’S OREXIN-1 (OX1) ANTAGONIST PROGRAM​\n* ‍INDIVIOR UK LIMITED AND C4X DISCOVERY HOLDINGS PLC ENTERED INTO A LICENSE AGREEMENT​\n* INDIVIOR - ‍UNDER AGREEMENT, INDIVIOR UK OBTAINED EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE C4X’S ORAL OREXIN-1 RECEPTOR ANTAGONIST PROGRAM​\n* INDIVIOR - ‍INDIVIOR UK WILL MAKE AN UPFRONT PAYMENT TO C4X OF $10 MILLION WITH POTENTIAL MILESTONE PAYMENTS TO C4X THAT COULD TOTAL $284 MILLION OVER TIME​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T15:11:00.000+03:00", "crawled": "2018-03-30T13:26:23.005+03:00", "highlightTitle": ""}